Calliditas is a clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs.
Company profile
Ticker
CALT
Exchange
Website
CEO
Renee J. Aguiar-Lucander
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
CALT stock data
Latest filings (excl ownership)
20-F
2023 FY
Annual report (foreign)
24 Apr 24
6-K
Current report (foreign)
6 Mar 24
6-K
Calliditas Year-end report, January – December 2023
21 Feb 24
6-K
Calliditas Therapeutics appoints Maria Törnsén as President North America
8 Jan 24
6-K
Current report (foreign)
27 Dec 23
6-K
Current report (foreign)
20 Dec 23
6-K
Current report (foreign)
11 Dec 23
6-K
Current report (foreign)
30 Nov 23
6-K
Calliditas’ partner Everest Medicines announces China NMPA’s approval of Nefecon® for the treatment of primary IgA nephropathy
24 Nov 23
6-K
Interim Report January – September 2023 Q3
7 Nov 23
Latest ownership filings
SC 13G/A
BIOTECHNOLOGY VALUE FUND L P
14 Feb 23
SC 13G/A
FJARDE AP-FONDEN /FOURTH SWEDISH NATIONAL PENSION FUND
1 Feb 23
SC 13G
Swedbank Robur Fonder AB
26 Jan 23
SC 13G
Linc AB
2 Mar 22
SC 13G
Swedbank Robur Fonder AB
14 Feb 22
SC 13G
FJARDE AP-FONDEN /FOURTH SWEDISH NATIONAL PENSION FUND
14 Feb 22
SC 13G/A
BIOTECHNOLOGY VALUE FUND L P
12 Nov 20
SC 13G
BIOTECHNOLOGY VALUE FUND L P
8 Jun 20
Financial summary
Quarter (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Institutional ownership, Q3 2023
42.4% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 19 |
Opened positions | 3 |
Closed positions | 1 |
Increased positions | 3 |
Reduced positions | 5 |
13F shares | Current |
---|---|
Total value | 16.37 bn |
Total shares | 12.64 mm |
Total puts | 27.60 k |
Total calls | 2.70 k |
Total put/call ratio | 10.2 |
Largest owners | Shares | Value |
---|---|---|
Biotechnology Value Fund L P | 6.26 mm | $0.00 |
Linc AB | 5.49 mm | $135.84 mm |
BVF | 750.00 k | $13.70 bn |
DB Deutsche Bank AG - Registered Shares | 90.55 k | $1.65 bn |
Ironwood Investment Management | 26.69 k | $487.32 mm |
Sphera Funds Management | 11.86 k | $216.62 mm |
Citadel Advisors | 4.96 k | $90.53 mm |
MS Morgan Stanley | 2.33 k | $42.51 mm |
Advisor | 1.17 k | $21.31 mm |
BAC Bank Of America | 756.00 | $13.81 mm |
News
Calliditas Announces NefIgArd Open Label Extension Results
24 Apr 24
Calliditas Therapeutics Presents Additional Data Analyses From Phase 3 NeflgArd Trial Of Nefecon In Primary IgA Nephropathy At ISN World Congress Of Nephrology 2024
18 Apr 24
Calliditas Receives Notice of Allowance for US Patent Application Covering Setanaxib in Cancer Treatment
8 Apr 24
Earlier Reported, Everest Medicines' Partner Calliditas Therapeutics Announces US FDA Grants an Additional Seven-Year Orphan Drug Exclusivity Period for Nefecon
12 Mar 24
Calliditas Bags An Additional Seven Year Orphan Drug Exclusivity Period For TARPEYO from the FDA
6 Mar 24
Press releases
Calliditas Therapeutics' 2023 Annual Report Published
24 Apr 24
Calliditas Announces Positive NefIgArd Open Label Extension Results
24 Apr 24
Calliditas Therapeutics Presents Additional Data Analyses from the Phase 3 NeflgArd trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024
18 Apr 24
Calliditas Therapeutics to Attend Conferences in April
9 Apr 24
Calliditas Therapeutics to Present Nefecon Data at the ISN World Congress of Nephrology April 13 - 16 in Buenos Aires
8 Apr 24